Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of KK2845 in relapsed or refractory acute myeloid leukemia and other hematologic malignancies
jRCT2011240008Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KK2845_3 in acute myeloid leukemia (AML) and hematopoietic malignancies, sponsored by Kyowa Kirin. Primary endpoint: Dose-limiting toxicity. Started Oct 2024; status: recruiting.
02
Drugs
KK2845_3
03
Conditions
acute myeloid leukemia (AML)hematopoietic malignancies
Beyond the preview
Go deeper on jRCT2011240008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240008.